CRESCENT BIOPHARMA, INC. — Director's Dealing 2017

Jun 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2017-06-15

Reporting Person: JUNIUS DANIEL M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-15	Common Stock	A	3000	$11.27	Acquired	8000	Direct

Footnotes

F1: The Reporting Person purchased the securities on the open market at purchase prices ranging from $11.24 to $11.29 per share, with a weighted average purchase price of $11.27 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.